Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21357283 | 0.87 | — | — | |
| SCHEMBL21357278 | 0.83 | IDO1 (0.37) | IDO1 | |
| SCHEMBL13036080 | 0.83 | IDO1 (0.37) | IDO1 | |
| SCHEMBL18614591 | 0.81 | IDO1 (0.36) | IDO1 | |
| SCHEMBL18614577 | 0.78 | IDO1 (0.38) | IDO1 | |
| SCHEMBL29308387 | 0.78 | IDO1 (0.38) | IDO1 | |
| Hydrochloric Acid SCHEMBL21083597 | 0.76 | IDO1 (0.37) | IDO1 | |
| SCHEMBL22906068 | 0.75 | IDO1 (0.41) | IDO1 | |
| SCHEMBL879699 | 0.75 | — | — | |
| SCHEMBL16302126 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448522-B1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IOMET PHARMA LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-20200230117-A1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IOMET PHARMA LTD. (GB) | 2020-07-23 | — | — | US | disclosed |
| WO-2017189386-A1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IOMET PHARMA LTD. (GB) | 2017-11-02 | — | — | WO | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230117-A1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IDO1, IDO2, TDO2 | IDO1 1/4885OPRM1 1888/4885NEK2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.